Clinical Trials List
2008-01-01 - 2009-04-30
Phase III
Terminated4
ICD-10I10
Essential (primary) hypertension
ICD-9401.0
Malignant essential hypertension
-
Trial Applicant
Boehringer Ingelheim
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/07/01
Investigators and Locations
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
- 顏學偉 Division of Cardiovascular Diseases
- 溫文才 Division of Cardiovascular Diseases
- Tsung-Hsien Lin Division of Cardiovascular Diseases
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Terminated
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Terminated
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
50 participants
-
Global
1012 participants
